Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,555 active trials61 approved drugs296 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,552 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,964)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03414047 | A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | completed | Phase 2 | 172 | Eli Lilly and CompanyINDUSTRY | 8 | Aug 19, 2022 | clinicaltrials |
| NCT03279250 | Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | completed | Phase 2 | 86 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT02716974 | A Study of Definitive Therapy to Treat Prostate Cancer(oligo-mets) | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT04424654 | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy(PSMA-BAT) | completed | Phase 2 | 20 | Hospital Sirio-LibanesOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT01590017 | Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer | completed | Phase 2 | 41 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 27, 2022 | clinicaltrials |
| NCT03029598 | Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT00238420 | Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Jul 19, 2022 | clinicaltrials |
| NCT02012296 | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 88 | University of ChicagoOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT01034631 | BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 154 | Hoosier Cancer Research NetworkOTHER | 3 | Jul 11, 2022 | clinicaltrials |
| NCT01524991 | First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | completed | Phase 2 | 36 | Hoosier Cancer Research NetworkOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT01780545 | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | completed | Phase 2 | 200 | Noah Hahn, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT01809379 | Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer | completed | Phase 2 | 69 | Ruhr University of BochumOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT03029780 | An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma(CheckMate 800) | completed | Phase 2 | 104 | Bristol-Myers SquibbINDUSTRY | 3 | Jun 29, 2022 | clinicaltrials |
| NCT02090114 | RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)(Restore) | completed | Phase 2 | 112 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT00450411 | Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy | completed | Phase 2 | 100 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT02317705 | Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer | completed | Phase 2 | 48 | On Target Laboratories, LLCINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02770391 | Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer | completed | Phase 2 | 54 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT00726596 | Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | completed | Phase 2 | 64 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT00777491 | Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery | completed | Phase 2 | 70 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 15, 2022 | clinicaltrials |
| NCT03392428 | A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer(TheraP) | completed | Phase 2 | 201 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT01434290 | Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 255 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 9, 2022 | clinicaltrials |
| NCT04475016 | TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer | completed | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT01157091 | Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer | completed | Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT01664182 | Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2022 | clinicaltrials |
| NCT00392821 | Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 78 | SCRI Development Innovations, LLCOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03373006 | A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer | completed | Phase 2 | 20 | HALO DiagnosticsINDUSTRY | 1 | May 25, 2022 | clinicaltrials |
| NCT03945084 | Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy | completed | Phase 2 | 58 | University of Turin, ItalyOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT00432094 | Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors | completed | Phase 2 | 23 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT00964002 | Efavirenz in Treating Patients With Metastatic Prostate Cancer(FAVE) | completed | Phase 2 | 61 | Institut BergoniéOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT01354431 | BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 168 | Bristol-Myers SquibbINDUSTRY | 4 | May 12, 2022 | clinicaltrials |
| NCT04436133 | Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) | completed | Phase 2 | 480 | National Vaccine and Serum Institute, ChinaINDUSTRY | 1 | May 6, 2022 | clinicaltrials |
| NCT02121639 | Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy(ProCAID) | completed | Phase 1 / Phase 2 | 160 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT02107937 | Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma | completed | Phase 2 | 136 | SOTIO a.s.INDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT03628716 | CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | completed | Phase 2 | 43 | Bavarian NordicINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT00126672 | RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT02268175 | Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | completed | Phase 2 | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT00181701 | Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | completed | Phase 2 | 46 | Massachusetts General HospitalOTHER | 0 | Apr 14, 2022 | clinicaltrials |
| NCT02983799 | Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status | completed | Phase 2 | 272 | AstraZenecaINDUSTRY | 2 | Apr 13, 2022 | clinicaltrials |
| NCT00853307 | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma | completed | Phase 2 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 8, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02614859 | Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients(BIMET-1) | completed | Phase 2 | 29 | Fox Chase Cancer CenterOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT01630590 | Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT02353832 | Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer | completed | Phase 2 | 44 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT02608684 | A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer(PemCiGem) | completed | Phase 2 | 21 | Cedars-Sinai Medical CenterOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT00003656 | Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 26 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04188847 | First-line Chemotherapy for Recurrent Cervical Cancer | completed | Phase 2 | 37 | Lei LiOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT04188860 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy | completed | Phase 2 | 34 | Lei LiOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT01513187 | Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 53 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Mar 10, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Aug 19, 2022source: clinicaltrials